Enveric Biosciences, Inc. (ENVB)
NASDAQ: ENVB · IEX Real-Time Price · USD
0.506
+0.036 (7.70%)
Jul 22, 2024, 10:00 AM EDT - Market open
Enveric Biosciences Employees
Enveric Biosciences had 7 employees as of December 31, 2023. The number of employees decreased by 19 or -73.08% compared to the previous year.
Employees
7
Change (1Y)
-19
Growth (1Y)
-73.08%
Revenue / Employee
n/a
Profits / Employee
-$2,159,261
Market Cap
4.14M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 7 | -19 | -73.08% |
| Dec 31, 2022 | 26 | 2 | 8.33% |
| Dec 31, 2021 | 24 | 21 | 700.00% |
| Dec 31, 2020 | 3 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Venus Concept | 304 |
| Regional Health Properties | 114 |
| Fresh2 Group | 75 |
| Avinger | 72 |
| Applied DNA Sciences | 55 |
| Sintx Technologies | 43 |
| Scinai Immunotherapeutics | 31 |
| Onconetix | 12 |
ENVB News
- 7 days ago - Aries Science & Technology and Enveric Biosciences Announce Licensing Agreement - Business Wire
- 12 days ago - Enveric Biosciences Announces Patent Granted for Drug Candidate - Business Wire
- 24 days ago - Diamond Equity Research Releases Update Note on Enveric Biosciences Inc. (NASDAQ: ENVB) - GlobeNewsWire
- 27 days ago - Enveric Biosciences Provides Strategic Outlook and Pipeline Update, Elevating EB-003 to Lead Development Candidate - Business Wire
- 7 weeks ago - Enveric Biosciences to Participate in BIO International Convention 2024 - Business Wire
- 2 months ago - Enveric Biosciences Reports First Quarter 2024 Financial and Corporate Results - Business Wire
- 2 months ago - Enveric Biosciences Signs $66.5 Million Non-Binding Term Sheet with MindBio Therapeutics to Out-License Novel Psilocin Prodrug Candidate for Mental Health Disorders - Accesswire
- 2 months ago - Enveric Biosciences Announces Signing of Non-Binding Term Sheet with Undisclosed Licensee for Exclusive License to Patented Methods of Treating Breast and Other Cancers Using Cannabinoids - Business Wire